Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 107

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 107
---
 relied on the inducement grant exception under Nasdaq Listing Rule 5635(c)(4) to grant nonstatutory stock options, restricted stock units (“RSUs”), and performance stock units (“PSUs”, and collectively, the “Inducement Awards”) to a newly hired executive officer who was eligible under the Nasdaq rules to receive such grants. We have relied on the inducement grant exception to make these grants to this officer in order to preserve shares available under the Current Plan to enable us to continue to make market-based, competitive equity grants to our current employees, non-employeedirectors and consultants who are not eligible to receive such inducement grants. 84

The following table includes information, as of March 31, 2025, regarding all of our outstanding equity awards under all of our equity-based compensation plans and arrangements under which shares of common stock may be issued. This includes shares subject to outstanding awards under the Current Plan and the 2013 Plan, Inducement Awards, and up to 1,215,876 shares that remain available for the grant of new awards under the Current Plan as of March 31, 2025, but does not include shares issuable under our Amended and Restated 2013 Employee Stock Purchase Plan.

| Number of outstanding stock options                                                                                                                                        |     |   |  6,378,183 |
|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:--|-----------:|
| Weighted average exercise price of outstanding stock options                                                                                                               |     | $ |      40.73 |
| Weighted average remaining contractual term of outstanding stock options (years)                                                                                           |     |   |        6.6 |
| Number of outstanding RSUs (including PSUs)(1)                                                                                                                             |     |   |  2,731,560 |
| Shares available for the grant of new awards under the Current Plan                                                                                                        |     |   |  1,215,876 |
| New shares requested for approval pursuant to the 2023 Plan Amendment                                                                                                      |     |   |  2,500,000 |
| Estimated total number of shares available for the grant of new awards under all equity-based compensation plans, assuming stockholder approval of the 2023 Plan Amendment |     |   |  3,715,876 |
| Number of shares of common stock outstanding                                                                                                                               |     |   | 57,886,781 |

| (1) | The target level of payout under our outstanding PS